{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-003329","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2025-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.233321+00:00","generated_at":"2026-05-23T18:35:03.643174+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cingulate receives $3M grant from private foundation to accelerate CTx-2103 (buspirone) development","bullets":["Grant of $3M in three $1M tranches; first payment May 1, 2025, others upon formulation and development milestones.","Non-dilutive funding; contingent royalty of $500K per quarter after first commercial sale, max cumulative $3.5M.","CTx-2103 (buspirone) potential first once-daily formulation for anxiety; U.S. market $5.5B, global $11.6B.","Grant expands pipeline and validates Cingulate's proprietary Precision Timed Release drug delivery platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-003329","json":"https://secwatch.observer/filing/0001641172-25-003329.json","markdown":"https://secwatch.observer/filing/0001641172-25-003329.md","text":"https://secwatch.observer/filing/0001641172-25-003329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000164117225003329/0001641172-25-003329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000164117225003329/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T18:35:03.643174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}